Expression of LMO4 and outcome in pancreatic ductal adenocarcinoma

Murphy, N.C. et al. (2008) Expression of LMO4 and outcome in pancreatic ductal adenocarcinoma. British Journal of Cancer, 98(3), pp. 537-541. (doi:10.1038/sj.bjc.6604177)

80796.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial Share Alike.



Identification of a biomarker of prognosis and response to therapy that can be assessed preoperatively would significantly improve overall outcomes for patients with pancreatic cancer. In this study, patients whose tumours exhibited high LMO4 expression had a significant survival advantage following operative resection, whereas the survival of those patients whose tumours had low or no LMO4 expression was not significantly different when resection was compared with operative biopsy alone.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Biankin, Professor Andrew
Authors: Murphy, N.C., Scarlett, C.J., Kench, J.G., Sum, E.Y.M., Segara, D., Colvin, E.K., Susanto, J., Cosman, P.H., Lee, C.-S., Musgrove, E.A., Sutherland, R.L., Lindeman, G.J., Henshall, S.M., Visvader, J.E., and Biankin, A.V.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:British Journal of Cancer
Publisher:Nature Publishing Group
ISSN (Online):1532-1827
Copyright Holders:Copyright © 2008 Cancer Research UK
First Published:First published in British Journal of Cancer 98(3):537-541
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record